SCHEMBL4874417

SCHEMBL4874417

CC(=O)c1cc(F)cnc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 3/20 0.39
AGBL2 Q5U5Z8 1/20 0.39
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
PIK3CB P42338 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAP4K4 O95819 2/20 0.36
KEAP1 Q14145 1/20 0.36
IKBKE Q14164 2/20 0.36
TBK1 Q9UHD2 2/20 0.36
MET P08581 1/20 0.35
CHRNA7 P36544 1/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31382799 1.00 PIK3C3 (0.39) PIK3C3AGBL2ALOX5APFEN1PIK3CB
SCHEMBL3258118 0.82 PIK3CB (0.47) PIK3CBMAP4K4KEAP1
SCHEMBL921542 0.82 KEAP1 (0.50) AGBL2MAP4K4KEAP1GABRPGABRD
SCHEMBL23079020 0.80 OPRK1 (0.46) IKBKETBK1
SCHEMBL16468484 0.80 AGBL2 (0.41) AGBL2ALOX5APFEN1SMN1; SMN2MAOB
SCHEMBL15081394 0.80 SMN1; SMN2 (0.39) PIK3C3PIK3CBSMN1; SMN2IKBKETBK1
SCHEMBL22996497 0.78 AGBL2 (0.40) AGBL2ALOX5APFEN1SMN1; SMN2MAOB
SCHEMBL13199604 0.78 NOS3 (0.52) PIK3C3PIK3CBSMN1; SMN2MAP4K4IKBKE
SCHEMBL4869343 0.77 SCN9A (0.39) PIK3CBSMN1; SMN2MAP4K4IKBKETBK1
SCHEMBL11992010 0.77 HTT (0.50) PIK3CBSMN1; SMN2IKBKETBK1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735451-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS Kumquat Biosciences Inc. (US) 2026-05-06 EP disclosed
WO-2025007000-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS KUMQUAT BIOSCIENCES INC. (US) 2025-01-02 WO disclosed
WO-2017039331-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2017-03-09 WO disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PDE5A, PDE3B, PDE12 PIK3C3 1115/4885AGBL2 1854/4885ALOX5AP 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.